Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
- Conditions
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 28
- Registration Number
- NCT02047253
- Locations
- 🇺🇸
University of Tulane, New Orleans, Louisiana, United States
🇺🇸Birmingham VA Medical Center, Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT02042950
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
- Conditions
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 77
- Registration Number
- NCT02036502
Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy
- Conditions
- Interventions
- First Posted Date
- 2013-12-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Attaya Suvannasankha
- Target Recruit Count
- 10
- Registration Number
- NCT02020941
- Locations
- 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Siyang Leng
- Target Recruit Count
- 20
- Registration Number
- NCT02002598
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 240
- Registration Number
- NCT01998971
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT01987232
- Locations
- 🇷🇺
State Budgetary Healthcare Institution of Yaroslavl Region "Regional Clinical Oncological Hospital", Yaroslavl, Russian Federation
🇺🇸Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇷🇺Regional Budgetary Healthcare Institution "Kursk Regional Clinical Oncology Dispensary", Kislino, Kursk, Russian Federation
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 22
- Registration Number
- NCT01980589
- Locations
- 🇺🇸
James R. Berenson, MD, West Hollywood, California, United States
🇺🇸California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸The Oncology Institute of Hope and Innovation, Whittier, California, United States
Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Emory University
- Target Recruit Count
- 1
- Registration Number
- NCT01969565
- Locations
- 🇺🇸
Winship Cancer Institute-Emory University, Atlanta, Georgia, United States
Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 84
- Registration Number
- NCT01962792
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.